RMD Resmed Inc

Price (delayed)

$253.29

Market cap

$36.91B

P/E Ratio

73.42

Dividend/share

$1.62

EPS

$3.45

Enterprise value

$37.58B

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory ...

Highlights
RMD's equity is up by 13% year-on-year and by 4.9% since the previous quarter
The company's revenue rose by 11% YoY and by 4.8% QoQ
Resmed's quick ratio has increased by 36% from the previous quarter but it has decreased by 9% YoY
The EPS has decreased by 27% YoY but it has increased by 6% from the previous quarter
The price to earnings (P/E) is 65% higher than the 5-year quarterly average of 44.6 and 14% higher than the last 4 quarters average of 64.3
Resmed's gross margin has decreased by 2.4% YoY

Key stats

What are the main financial stats of RMD
Market
Shares outstanding
145.72M
Market cap
$36.91B
Enterprise value
$37.58B
Valuations
Price to earnings (P/E)
73.42
Price to book (P/B)
12.19
Price to sales (P/S)
11.02
EV/EBIT
39.82
EV/EBITDA
33.17
EV/Sales
11.22
Earnings
Revenue
$3.35B
EBIT
$943.74M
EBITDA
$1.13B
Free cash flow
$410.51M
Per share
EPS
$3.45
Free cash flow per share
$2.82
Book value per share
$20.77
Revenue per share
$22.99
TBVPS
$16.69
Balance sheet
Total assets
$4.73B
Total liabilities
$1.7B
Debt
$950.11M
Equity
$3.03B
Working capital
$962.1M
Liquidity
Debt to equity
0.31
Current ratio
2.54
Quick ratio
1.36
Net debt/EBITDA
0.59
Margins
EBITDA margin
33.8%
Gross margin
56.9%
Net margin
14.9%
Operating margin
28.3%
Efficiency
Return on assets
10.7%
Return on equity
17.4%
Return on invested capital
42.6%
Return on capital employed
23%
Return on sales
28.2%
Dividend
Dividend yield
0.64%
DPS
$1.62
Payout ratio
47%

RMD stock price

How has the Resmed stock price performed over time
Intraday
-0.61%
1 week
-0.67%
1 month
-4.4%
1 year
19.7%
YTD
19.16%
QTD
-3.89%

Financial performance

How have Resmed's revenue and profit performed over time
Revenue
$3.35B
Gross profit
$1.91B
Operating income
$948.69M
Net income
$499.75M
Gross margin
56.9%
Net margin
14.9%
Resmed's net margin has decreased by 34% YoY
RMD's net income is down by 26% YoY but it is up by 5% QoQ
The company's revenue rose by 11% YoY and by 4.8% QoQ
RMD's operating income is up by 11% YoY and by 5% QoQ

Growth

What is Resmed's growth rate over time

Valuation

What is Resmed stock price valuation
P/E
73.42
P/B
12.19
P/S
11.02
EV/EBIT
39.82
EV/EBITDA
33.17
EV/Sales
11.22
The price to earnings (P/E) is 65% higher than the 5-year quarterly average of 44.6 and 14% higher than the last 4 quarters average of 64.3
The EPS has decreased by 27% YoY but it has increased by 6% from the previous quarter
RMD's P/B is 43% above its 5-year quarterly average of 8.5 and 5% above its last 4 quarters average of 11.6
RMD's equity is up by 13% year-on-year and by 4.9% since the previous quarter
The P/S is 51% higher than the 5-year quarterly average of 7.3 and 6% higher than the last 4 quarters average of 10.4
The company's revenue rose by 11% YoY and by 4.8% QoQ

Efficiency

How efficient is Resmed business performance
Resmed's ROE has decreased by 38% YoY but it has increased by 2.4% from the previous quarter
The company's return on invested capital rose by 34% YoY and by 3.9% QoQ
The ROA has decreased by 29% YoY but it has increased by 3.9% from the previous quarter
The ROS has increased by 3.3% YoY

Dividends

What is RMD's dividend history
DPS
$1.62
Dividend yield
0.64%
Payout ratio
47%
Recent dividends

Financial health

How did Resmed financials performed over time
The company's total assets is 178% higher than its total liabilities
The current ratio has grown by 47% from the previous quarter but it has contracted by 2.7% YoY
Resmed's quick ratio has increased by 36% from the previous quarter but it has decreased by 9% YoY
Resmed's debt is 69% lower than its equity
Resmed's debt to equity has decreased by 30% YoY but it has increased by 11% QoQ
Resmed's debt has decreased by 20% YoY but it has increased by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.